Development
ImmunoPrecise Antibodies Ltd.
IPA
$0.6724
-$0.0296-4.22%
NASDAQ
| 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 16.26% | 16.99% | 0.35% | 0.94% | 3.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.26% | 16.99% | 0.35% | 0.94% | 3.69% |
| Cost of Revenue | 30.24% | 26.24% | 10.89% | -6.93% | 5.80% |
| Gross Profit | 4.18% | 8.73% | -5.76% | 7.73% | 1.92% |
| SG&A Expenses | -10.83% | 4.19% | -0.11% | 18.85% | 18.17% |
| Depreciation & Amortization | -26.88% | -26.54% | 145.34% | 93.44% | 78.58% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.89% | -35.55% | 0.93% | 0.47% | 30.56% |
| Operating Income | 62.13% | 60.00% | -1.84% | 0.05% | -57.62% |
| Income Before Tax | 66.05% | 62.28% | -26.22% | -19.37% | -46.54% |
| Income Tax Expenses | 124.92% | 37.29% | -360.85% | -52.98% | -162.63% |
| Earnings from Continuing Operations | 65.04% | 63.35% | -3.30% | -15.44% | -38.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.04% | 63.35% | -3.30% | -15.44% | -38.60% |
| EBIT | 62.13% | 60.00% | -1.84% | 0.05% | -57.62% |
| EBITDA | 61.89% | 67.87% | 17.14% | -15.83% | -60.13% |
| EPS Basic | 65.29% | 63.79% | 14.33% | 10.04% | -7.82% |
| Normalized Basic EPS | 66.29% | 62.73% | 27.42% | 7.54% | -13.96% |
| EPS Diluted | 65.29% | 63.79% | 14.33% | 10.04% | -7.82% |
| Normalized Diluted EPS | 66.29% | 62.73% | 27.42% | 7.54% | -13.96% |
| Average Basic Shares Outstanding | 0.71% | 1.26% | 20.59% | 28.39% | 28.58% |
| Average Diluted Shares Outstanding | 0.71% | 1.26% | 20.59% | 28.39% | 28.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |